Publication: Pitfalls in genetic testing: the story of missed SCN1A mutations
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley and Sons Inc.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Djémié, T., S. Weckhuysen, S. von Spiczak, G. L. Carvill, J. Jaehn, A. Anttonen, E. Brilstra, et al. 2016. “Pitfalls in genetic testing: the story of missed SCN1A mutations.” Molecular Genetics & Genomic Medicine 4 (4): 457-464. doi:10.1002/mgg3.217. http://dx.doi.org/10.1002/mgg3.217.
Research Data
Abstract
Abstract Background: Sanger sequencing, still the standard technique for genetic testing in most diagnostic laboratories and until recently widely used in research, is gradually being complemented by next‐generation sequencing (NGS). No single mutation detection technique is however perfect in identifying all mutations. Therefore, we wondered to what extent inconsistencies between Sanger sequencing and NGS affect the molecular diagnosis of patients. Since mutations in SCN1A, the major gene implicated in epilepsy, are found in the majority of Dravet syndrome (DS) patients, we focused on missed SCN1A mutations. Methods: We sent out a survey to 16 genetic centers performing SCN1A testing. Results: We collected data on 28 mutations initially missed using Sanger sequencing. All patients were falsely reported as SCN1A mutation‐negative, both due to technical limitations and human errors. Conclusion: We illustrate the pitfalls of Sanger sequencing and most importantly provide evidence that SCN1A mutations are an even more frequent cause of DS than already anticipated.
Description
Other Available Sources
Keywords
Original Article, Dravet syndrome, epilepsy, genetic screening, next‐generation sequencing, Sanger sequencing
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service